Related Experiment Video
Updated: May 8, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?
Andreea Ioana Parosanu1,2, Cornelia Nititpir1,2, Ioana Miruna Stanciu1,2
1Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania.
Abstract:
Surgery is the oldest modality of kidney cancer therapy and is usually the first step in the treatment process. To improve surgical outcomes, adjuvant therapy is frequently administered to eliminate residual tumors and reduce the risk of recurrence and metastasis. However, not all patients require adjuvant treatment. The decision regarding whether to treat or not to treat renal cell carcinoma patients depends on the risk of recurrence, including tumor stage and histology, and clinical, biological, and personal risk factors. This article will address the challenges of treating renal cell carcinoma patients with adjuvant therapy and review the current evidence and ongoing clinical trials.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Kidney Transplant II: Surgical Procedure
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease III: Interprofessional Care

